SCHEMBL6168520

SCHEMBL6168520

O=C(O)c1ccc2c(c1)nc(Cc1ccccc1)n2Cc1ccc(Cl)cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.53
JAK1 P23458 1/20 0.53
TYK2 P29597 1/20 0.53
JAK3 P52333 1/20 0.53
TP53 P04637 2/20 0.52
MAPT P10636 1/20 0.52
CNR1 P21554 1/20 0.50
CNR2 P34972 1/20 0.50
VDR P11473 1/20 0.50
DRD2 P14416 1/20 0.50
TBXA2R P21731 1/20 0.50
POLB P06746 1/20 0.50
ALOX5AP P20292 2/20 0.49
LMNA P02545 2/20 0.48
GNRHR P30968 1/20 0.47
BCHE P06276 1/20 0.46
ACHE P22303 1/20 0.46
CCR2 P41597 2/20 0.46
HCAR3 P49019 1/20 0.46
CA12 O43570 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6169301 0.92 TP53 (0.52) TP53MAPTVDRDRD2TBXA2R
SCHEMBL6168734 0.90 ALOX5AP (0.59) JAK2JAK1TYK2JAK3TP53
SCHEMBL6171449 0.88 CNR2 (0.54) JAK2JAK1TYK2JAK3TP53
SCHEMBL1160435 0.85 GNRHR (0.51) JAK2JAK1TYK2JAK3TP53
SCHEMBL13508741 0.84 LMNA (0.68) TP53MAPTVDRDRD2TBXA2R
SCHEMBL6170162 0.82 ALOX5AP (0.54) JAK2JAK1TYK2JAK3TP53
SCHEMBL6172342 0.81 PPARG (0.54) VDRALOX5APLMNA
SCHEMBL6171260 0.80 DRD2 (0.52) TP53MAPTCNR1CNR2VDR
SCHEMBL6171536 0.78 CNR2 (0.56) JAK2JAK1TYK2JAK3TP53
SCHEMBL1178232 0.78 PPARG (0.53) TP53MAPTVDRDRD2TBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0882718-B1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2005-08-31 EP disclosed
US-6352985-B1 CARDIOVASCULAR DISORDERS OR GASTROINTESTINAL DISORDERS, DIABETES (TYPE II DIABETES), DIABETIC COMPLICATIONS METHOD FOR LOWERING THE BLOOD SUGAR LEVEL OF A PATIENT, FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-03-05 US disclosed
US-6211177-B1 SIDE EFFECT REDUCTION CELL PATHWAYS, INC. 2001-04-03 US disclosed
US-6166219-A Benzimidazole derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-12-26 US disclosed
EP-0882718-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-12-09 EP disclosed